Druck Icon
 

Eckert & Ziegler Reorganizes its Production Sites

Insider information pursuant to Article 17 MAR

-Sale of Belgian special purpose property initiated
-One-off income expected

Berlin, 5 March 2020. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX) will reorganize its global network of radiopharmaceutical production sites and in this context sell a special property in Seneffe, Belgium. A corresponding agreement was notarised today and, in addition to the sale of the building, also includes the transfer of the handling license and liability for any dismantling obligations. The transfer is subject to customary market conditions precedent. The necessary conditions include in particular the approval of the Belgian supervisory authority. The transfer and the associated effects on the balance sheet will only become effective once the supervisory authority has issued a positive decision.

If the authority approves the transfer as requested, this would result in a release of the disposal reserves previously held for the Belgian production building. This change in the balance sheet would result in a one-off income of 2.7 Mio. EUR for Eckert & Ziegler.

Explanation:
With the merger of the Belgian prostate implant specialist IBt in 2008, Eckert & Ziegler BEBIG SA took over a production site where cyclotrons were used to produce precursors for low-level radioactive implants. Since new production sites are planned in Asia and North America as part of a realignment and globalization of the Pharmaceuticals division, Eckert & Ziegler is now divesting from this special property.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@dont-want-spam.ezag.de, www.ezag.de